Immunorestoration of Immunodeficiency by Biological Response Modifiers

  • Robert K. Oldham
Part of the University of South Florida International Biomedical Symposia Series book series (USFIBSS)


It is well known that there are many mediators which are important in the generation and execution of immune responses. These mediators, when generated by lymphoid cells or when acting on lymphoid targets, have been termed lymphokines and those acting on non-lymphoid targets have been named cytokines. The combination term “lymphokine/cytokine” has been used to refer to the general class of soluble substances mediating biological responses in cell-cell interactions. These substances are distinct from, although similar to, hormones which are generally secreted by cells within the endocrine system acting on a remote target.


Natural Killer Cell Chronic Lymphocytic Leukemia Alpha Interferon Roswell Park Memorial Institute Biological Response Modifier 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. K. Oldham, Biologicals and biological response modifiers: fourth modality of cancer treatment, Cancer Treat. Rpt. 68 (1): 221 (1984).Google Scholar
  2. 2.
    B. H. Waksman, Overview: biology of the lymphokines, in: “Biology of Lymphokines,” eds., Academic Press (1979).Google Scholar
  3. 3.
    R. K. Oldham, G. N. Thurman, J. E. Talmadge, et al., Lymphokines, monoclonal antibodies and other biological response modifiers in the treatment of cancer, Cancer 1(54) (Supp. 11 ): 2795 (1984).CrossRefGoogle Scholar
  4. 4.
    R. K. Oldham, Biological response modifiers program, Biol. Resp. Modif. 1: 81 (1982).Google Scholar
  5. 5.
    I. J. Fidler, M. Berendt, and R. K. Oldham, The rationale for design of screening assays for the assessment of biological response modifiers for cancer treatment, J. Biol. Resp. Modif. 1: 15 (1982).Google Scholar
  6. 6.
    J. E. Talmadge, R. K. Oldham, and I. J. Fidler, Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers, J. Biol. Resp. Modif. 3: 88 (1984).Google Scholar
  7. 7.
    N. Flomenberg, K. Welte, R. Mertelsmann, et al., Immunologic effects of interleukin 2 in primary immunodeficiency diseases. IV. J. Immunol. 130: 2644 (1983).PubMedGoogle Scholar
  8. 8.
    S. A. Sherwin, J. A. Knost, S. Fein, et al., A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients, JAMA 248: 2461 (1982).PubMedCrossRefGoogle Scholar
  9. 8.
    S. A. Sherwin, J. A. Knost, S. Fein, et al., A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients, JAMA 248: 2461 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    K. A. Foon, S. A. Sherwin, P. G. Abrams, et al., Recombinant leukocyte A interferon: an effective agent for the treatment of advanced non-Hodgkin’s lymphoma, N. Eng. J. Med. 311 (18): 1148 (1984).CrossRefGoogle Scholar
  11. 11.
    P. A. Bunn, Jr., K. A. Foon, D. C. Idhe, et al., Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas, Annals Int. Med. 101 (4): 484 (1984).Google Scholar
  12. 12.
    J. M. Kirkwood and M. S. Ernstoff, Interferons in the treatment of human cancer, J. Clin. Oncol. 2: 336 (1984).PubMedGoogle Scholar
  13. 13.
    R. K. Oldham, Monoclonal antibodies in cancer therapy, J. Clin. Oncol. 1: 582 (1983).PubMedGoogle Scholar
  14. 14.
    R. K. Oldham, K. A. Foon, A. C. Morgan, et al., Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration, Clin. Oncol. 2 (11): 1235 (1984).Google Scholar
  15. 15.
    A. B. Cosimi, R. B. Colvin, R. C. Burton, et al., Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts, N. Eng. J. Med. 305: 308 (1981).CrossRefGoogle Scholar
  16. 16.
    K. A. Foon, R. W. Schroff, P. A. Bunn, et al., Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia, Blood 64 (5): 1085 (1984).PubMedGoogle Scholar
  17. 17.
    R. W. Schroff, K. A. Foon, S. B. Wilburn, et al., Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy, Cancer Res. 45 (2): 879 (1985).PubMedGoogle Scholar
  18. 18.
    R. A. Miller, D. G. Maloney, R. Warnke, et al., Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody, N. Eng. J. Med. 306: 517 (1982).CrossRefGoogle Scholar
  19. 19.
    S. L. Giardina, R. W. Schroff, C. S. Woodhouse, et al., Detection of two distinct malignant B-cell clones in a single patient using anti-idiotype monoclonal antibodies and immunoglobulin in gene rearrangement, (submitted, 1984 ).Google Scholar
  20. 20.
    R. K. Oldham and R. V. Smalley, Immunotherapy: the old and the new, J. Biol. Resp. Modif. 2: 1 (1983).Google Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Robert K. Oldham
    • 1
  1. 1.Institute for Biological TherapyUniversity of British ColumbiaVancouverCanada

Personalised recommendations